These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 24216483

  • 1. Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.
    Inoue D, Kitaura J, Togami K, Nishimura K, Enomoto Y, Uchida T, Kagiyama Y, Kawabata KC, Nakahara F, Izawa K, Oki T, Maehara A, Isobe M, Tsuchiya A, Harada Y, Harada H, Ochiya T, Aburatani H, Kimura H, Thol F, Heuser M, Levine RL, Abdel-Wahab O, Kitamura T.
    J Clin Invest; 2013 Nov; 123(11):4627-40. PubMed ID: 24216483
    [Abstract] [Full Text] [Related]

  • 2. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
    Inoue D, Kitaura J, Matsui H, Hou HA, Chou WC, Nagamachi A, Kawabata KC, Togami K, Nagase R, Horikawa S, Saika M, Micol JB, Hayashi Y, Harada Y, Harada H, Inaba T, Tien HF, Abdel-Wahab O, Kitamura T.
    Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
    [Abstract] [Full Text] [Related]

  • 3. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
    Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Aifantis I, Bernstein BE, Levine RL.
    Cancer Cell; 2012 Aug 14; 22(2):180-93. PubMed ID: 22897849
    [Abstract] [Full Text] [Related]

  • 4. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo.
    Abdel-Wahab O, Gao J, Adli M, Dey A, Trimarchi T, Chung YR, Kuscu C, Hricik T, Ndiaye-Lobry D, Lafave LM, Koche R, Shih AH, Guryanova OA, Kim E, Li S, Pandey S, Shin JY, Telis L, Liu J, Bhatt PK, Monette S, Zhao X, Mason CE, Park CY, Bernstein BE, Aifantis I, Levine RL.
    J Exp Med; 2013 Nov 18; 210(12):2641-59. PubMed ID: 24218140
    [Abstract] [Full Text] [Related]

  • 5. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.
    Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C, Hess JL, Humphries RK, Brock HW.
    Blood; 2010 Jan 07; 115(1):38-46. PubMed ID: 19861679
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Yang L, Wei X, Gong Y.
    Cancer Med; 2024 Jan 07; 13(1):e6871. PubMed ID: 38146893
    [Abstract] [Full Text] [Related]

  • 8. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S, Kitamura T.
    Int J Hematol; 2019 Aug 07; 110(2):179-186. PubMed ID: 30515738
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R, Chiu MC, Huang YJ, Lin TH, Kuo MC, Shih LY.
    J Hematol Oncol; 2019 Oct 22; 12(1):104. PubMed ID: 31640815
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Role of ASXL1 mutation in myeloid malignancies].
    Sheng MY, Zhou Y, Xu MJ, Yang FC.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug 22; 22(4):1183-7. PubMed ID: 25130853
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The role of ASXL1 in hematopoiesis and myeloid malignancies.
    Asada S, Fujino T, Goyama S, Kitamura T.
    Cell Mol Life Sci; 2019 Jul 22; 76(13):2511-2523. PubMed ID: 30927018
    [Abstract] [Full Text] [Related]

  • 17. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C, Burillo-Sanz S, Morales-Camacho RM, Pérez-López O, Suito M, Vargas MT, Caballero-Velázquez T, Carrillo-Cruz E, González J, Bernal R, Pérez-Simón JA.
    Cancer Med; 2020 Jun 22; 9(11):3637-3646. PubMed ID: 32216059
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis.
    Lin Y, Zheng Y, Wang ZC, Wang SY.
    Hematology; 2016 Sep 22; 21(8):454-61. PubMed ID: 27077763
    [Abstract] [Full Text] [Related]

  • 19. Epigenetic regulation by ASXL1 in myeloid malignancies.
    Yang FC, Agosto-Peña J.
    Int J Hematol; 2023 Jun 22; 117(6):791-806. PubMed ID: 37062051
    [Abstract] [Full Text] [Related]

  • 20. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Takeda R, Asada S, Park SJ, Yokoyama A, Becker HJ, Kanai A, Visconte V, Hershberger C, Hayashi Y, Yonezawa T, Tamura M, Fukushima T, Tanaka Y, Fukuyama T, Matsumoto A, Yamasaki S, Nakai K, Yamazaki S, Inaba T, Shibata T, Inoue D, Honda H, Goyama S, Maciejewski JP, Kitamura T.
    Blood; 2020 Oct 01; 136(14):1670-1684. PubMed ID: 32492700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.